Bulletin du cancer最新文献_第3页

MARVELD1 inhibits Neuro2a cell migration and tumorigenesis via regulating the transcriptional coactivators and protein methylation.

Bulletin du cancer Pub Date : 2025-03-13 DOI: 10.1016/j.bulcan.2025.01.010

Weizhe Liu, Yucui Dong, Ruiying Guo, Dingyan Zhou, Yiping Qin, Yuetao Ma, Juanjuan Zhang, Aiying Li

{"title":"MARVELD1 inhibits Neuro2a cell migration and tumorigenesis via regulating the transcriptional coactivators and protein methylation.","authors":"Weizhe Liu, Yucui Dong, Ruiying Guo, Dingyan Zhou, Yiping Qin, Yuetao Ma, Juanjuan Zhang, Aiying Li","doi":"10.1016/j.bulcan.2025.01.010","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.01.010","url":null,"abstract":"Neuronal cell proliferation and migration play an important regulatory role in the development and tumorigenesis of the nervous system. MARVEL domain-containing protein 1 (MARVELD1) is a potential tumor suppressor gene whose function in nervous system diseases is unclear. This study aimed to analyze the function and molecular mechanism of MARVELD1 gene in Neuro2a cell migration and tumor growth. We found that MARVELD1 could inhibit the tumor development with low-expression of Ki67, high-expression of cleaved-caspase3 and strong signal TUNEL staining. Moreover, MARVELD1 suppressed migration and epithelial to mesenchymal transition process in Neuro2a cells. Mass spectrometry analysis indicated that MARVELD1 could bind to PPP1CB, PPP1CC and NRAS. The RNA-sequencing analysis showed that MARVELD1 regulated transcriptional coactivators and protein methylation. These genes ultimately affected the pathways related to cell migration. These data highlight the potential usefulness of MARVELD1 as a potential target for preventing nervous system tumor genesis and metastasis.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143630474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Primary cutaneous/subcutaneous Ewings sarcoma.

Bulletin du cancer Pub Date : 2025-03-11 DOI: 10.1016/j.bulcan.2023.10.011

Thibaud Valentin, Sarah Winter, Valentine Martin, Marie Csanyi, Perrine Marec Berard, Valérie Laurence, Nathalie Gaspar

{"title":"Primary cutaneous/subcutaneous Ewings sarcoma.","authors":"Thibaud Valentin, Sarah Winter, Valentine Martin, Marie Csanyi, Perrine Marec Berard, Valérie Laurence, Nathalie Gaspar","doi":"10.1016/j.bulcan.2023.10.011","DOIUrl":"https://doi.org/10.1016/j.bulcan.2023.10.011","url":null,"abstract":"Amongst Ewing sarcoma family of tumours, (EFST), cutaneous/subcutaneous Ewing sarcoma are defined as tumours arising from cutaneous or subcutaneous tissue, not invading the underlying aponeurosis. They are rare tumours, with less than 200 patients published. They are typically small tumours (less than 5cm), and can arise at any anatomical location, with a particular tropism for distal, truncal and head/neck locations, compared to classical Ewing sarcoma. Like other conjunctive tumours, they have to be treated in specialized centers, with a diagnostic procedure following ESMO guidelines about soft-tissue tumours, favoring a core needle biopsy in most cases. They share classical pathological and molecular features of EFST (including EWSR1 rearrangement). Metastatic presentation is rare (less than 5% at diagnosis), but must be carefully searched using appropriated imaging considered the bad prognosis of these patients. Treatment strategy relies on neoadjuvant and adjuvant chemotherapy, surrounding the local treatment. Patients with localized disease have good prognosis and have to be treated with the dual objective of curability, and of minimizing acute and late toxicity. That is why in case of small tumours (<200mL), patients can be treated with less intensive protocols, as Saint Jude's (low-dose semi-continuous cyclophosphamide/doxorubicin regimen as induction chemotherapy and vincristine/actinomycin courses as maintenance therapy), setting aside the option of classical VDC/IE protocol for larger tumors. Local treatment must rely on carcinologic surgery, with the aim to avoid radiotherapy when possible. Patients with metastatic disease have bad prognosis resemble classical Ewing sarcoma, and have to be treated accordingly.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143617233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Merkel cell carcinoma: An update].

Bulletin du cancer Pub Date : 2025-03-11 DOI: 10.1016/j.bulcan.2024.11.013

Louise Toumelin, Thibault Kervarrec, Laurent Mortier, Philippe Saiag, Astrid Blom, Mahtab Samimi

{"title":"[Merkel cell carcinoma: An update].","authors":"Louise Toumelin, Thibault Kervarrec, Laurent Mortier, Philippe Saiag, Astrid Blom, Mahtab Samimi","doi":"10.1016/j.bulcan.2024.11.013","DOIUrl":"https://doi.org/10.1016/j.bulcan.2024.11.013","url":null,"abstract":"Merkel cell carcinoma (MCC) is a rare skin cancer that mainly affects the elderly, and whose incidence is increasing. Although the exact origin of this cancer remains uncertain, research in recent years has revealed that MCC develops through two oncogenesis pathways: virally induced by the Merkel polyomavirus (80% of cases) and induced by mutations linked to ultraviolet rays (20% of cases). MCC is an aggressive cancer, with a high mortality rate and limited therapeutic options in advanced stage. In localized stages, the recommendations remain surgical excision, with almost systematic additional treatment by radiotherapy to reduce the risk of recurrence; there is currently no approved recommendation for adjuvant immunotherapy at this stage. In advanced stages, PD-1/PD-L1 inhibitors as monotherapy have considerably improved the prognosis of patients and are recommended as first-line therapy. However, more than 50 % of patients have primary or secondary failure of these treatments, with no satisfactory option available to date. The use of dual immunotherapy ipilimumab/nivolumab in these refractory patients, or new strategies such as adjuvant or neoadjuvant immunotherapy, are the strategies currently being explored. This article will review the current guidelines on the management of MCC with a summary of the most recent scientific advances.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143618059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Extra-pulmonary metastatic Ewing sarcoma: The French GroupOs diagnostic and therapeutic recommendations].

Bulletin du cancer Pub Date : 2025-03-11 DOI: 10.1016/j.bulcan.2024.01.014

Sarah Winter, Thibaud Valentin, Anne Ducassou, Sylvie Helfre, Pablo Berlanga, Lauriane Lemelle, Aude Marie-Cardine, Pascaline Boudou Rouquette, Valérie Laurence

{"title":"[Extra-pulmonary metastatic Ewing sarcoma: The French GroupOs diagnostic and therapeutic recommendations].","authors":"Sarah Winter, Thibaud Valentin, Anne Ducassou, Sylvie Helfre, Pablo Berlanga, Lauriane Lemelle, Aude Marie-Cardine, Pascaline Boudou Rouquette, Valérie Laurence","doi":"10.1016/j.bulcan.2024.01.014","DOIUrl":"https://doi.org/10.1016/j.bulcan.2024.01.014","url":null,"abstract":"Patients who develop Ewing sarcoma with extra-pulmonary metastasis have a poor prognosis. A recent French protocol, CombinaiR3, was set up to evaluate the efficacy of induction chemotherapy followed by high-dose chemotherapy and metronomic maintenance treatment. It is now closed for inclusions and while waiting for the results, we propose a French consensus guideline for the management of patients diagnosed with Ewing sarcoma with extra-pulmonary dissemination. Main recommendations include induction chemotherapy with nine cycles of vincristine/doxorubicin/cyclophosphamide alternating with ifosfamide/etoposide. In case of insufficient response, other chemotherapy combination or inclusion in a clinical trial should be considered. Induction chemotherapy should be followed by local treatment, consisting of surgery and/or radiotherapy. Optimal local treatment is a milestone in the management of patients with Ewing sarcoma and should be discussed with experts and surgeons/radiotherapists working in the sarcoma network. High-dose chemotherapy (HDC) containing busulfan and melphalan followed by autologous stem-cell transplantation is still unclear, with contradictory results. HDC will then be discussed in national tumor board and administered to patients when compatible with local treatment. Given the high relapse rate observed among these metastatic patients, maintenance chemotherapy (so called metronomic regimen) will then be given for two years.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143618058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Recommendations from the group of bone tumors of the French Childhood Cancer Society and the French Sarcoma Group/Group for the Study of Bone Tumors].

Bulletin du cancer Pub Date : 2025-03-10 DOI: 10.1016/j.bulcan.2024.03.009

Morbize Julieron, Anne Gomez-Mascard, Cécile Vérité, Maud Toulmonde, Cyril Lervat, Michèle Kind, Juliette Thariat

{"title":"[Recommendations from the group of bone tumors of the French Childhood Cancer Society and the French Sarcoma Group/Group for the Study of Bone Tumors].","authors":"Morbize Julieron, Anne Gomez-Mascard, Cécile Vérité, Maud Toulmonde, Cyril Lervat, Michèle Kind, Juliette Thariat","doi":"10.1016/j.bulcan.2024.03.009","DOIUrl":"https://doi.org/10.1016/j.bulcan.2024.03.009","url":null,"abstract":"Osteosarcomas of the mandible represent 3-8% of osteosarcomas. The rarity of this anatomic site and its specific treatment explain that only retrospective and a few prospective studies are available in literature. However, there is a consistent evidence on the natural history and treatment of these tumors, which clearly differentiates them from osteosarcomas of the long bones. The aim of this study was to draw up recommendations based on these data and on a retrospective study by the French Sarcoma Group (GSF-GETO). Osteosarcomas of the mandible should be centrally reviewed by an expert pathologist. MDM2, GNAS and RASAL1 status should be checked, and a fragment should be frozen. Complete surgical resection with wide margins is the cornerstone of treatment. Mandibular reconstruction techniques can reduce the sequelae. Contrary to the validated treatment for osteosarcomas of limbs, the role of chemotherapy to prevent metastasis or local recurrence has yet to be clarified for mandibular osteosarcomas. The role of postoperative radiotherapy, in adults, should be discussed for these tumors, whose wide soft-tissue resection may be difficult to confirm. In children, adjuvant chemotherapy is preferable in cases of uncertain/possibly incomplete resection. Relapse of mandibular osteosarcomas is primarily local. Pulmonary metastases are delayed and less frequent than in long-bone osteosarcomas. The overall survival rate at five years is about 70%.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143607587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment guidelines/propositions, on behalf of French multidisciplinary working group on bone primary tumours GroupOs. 治疗指南/建议，代表法国骨原发性肿瘤多学科工作组。

Bulletin du cancer Pub Date : 2025-03-10 DOI: 10.1016/j.bulcan.2025.01.012

Valentine Martin, Stéphanie Bolle, Line Claude, Sylvie Helfre, Nathalie Gaspar

引用次数: 0

[Management of bone sarcomas in France: A special issue of GroupOs].

Bulletin du cancer Pub Date : 2025-03-08 DOI: 10.1016/j.bulcan.2025.02.002

Pascaline Boudou-Rouquette, Line Claude, Frédérique Larousserie, François Gouin, Nathalie Gaspar

引用次数: 0

[GroupOS welcomed guidelines].

Bulletin du cancer Pub Date : 2025-03-07 DOI: 10.1016/j.bulcan.2025.02.003

Daniel Orbach, Virginie Gandemer, Isabelle Pellier

引用次数: 0

[Adjuvant and neoadjuvant treatments of melanoma].

Bulletin du cancer Pub Date : 2025-02-28 DOI: 10.1016/j.bulcan.2024.11.014

Joséphine Cazals de Fabel, Caroline Gaudy-Marqueste

{"title":"[Adjuvant and neoadjuvant treatments of melanoma].","authors":"Joséphine Cazals de Fabel, Caroline Gaudy-Marqueste","doi":"10.1016/j.bulcan.2024.11.014","DOIUrl":"https://doi.org/10.1016/j.bulcan.2024.11.014","url":null,"abstract":"The management of melanoma has evolved significantly over the past decade with the advent of immunotherapies and BRAF/MEK inhibitors, which have changed the prognosis for patients with advanced disease. Having demonstrated their efficacy in advanced disease, these treatments have been evaluated and shown to be effective in adjuvant treatment at earlier stages, first in stage III and then in stage IIB-IIC. Alongside the development of these adjuvant treatments, which have become the standard of care, new therapeutic strategies have emerged. Neoadjuvant treatments have been shown to be superior to adjuvant treatments in phase II and III trials. These neoadjuvant strategies will undoubtedly become the new standard for patients with macroscopic lymph node disease. However, there are still many unanswered questions regarding the optimal treatment regimen. Should mono- or bi-immunotherapy be used? Can surgery be de-escalated? Is additional adjuvant treatment essential or can it be withheld in the event of a major pathological response? Should patients with BRAFV600 mutations switch to targeted therapies in the event of pathological non-response? Should we switch to targeted therapies in the event of pathological non-response in BRAFV600 mutant patients? Therapeutic strategies, which are becoming increasingly personalised, are evolving very rapidly, with a trend towards de-escalation. We still lack robust biomarkers for patient selection.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143538241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Ethical issues in long-term follow-up of pediatric cancers]. [儿科癌症长期随访的伦理问题]。

Bulletin du cancer Pub Date : 2025-02-27 DOI: 10.1016/j.bulcan.2024.12.018

Agathe Camus, Julie Henry, Claire Berger, Amandine Bertrand, Agnès Dumas, Marine Da Silva Sé, Sabine Heinrich, Tanguy Leprince, Gérard Michel, Christelle Riberon, Charlotte Demoor-Goldschmidt

{"title":"[Ethical issues in long-term follow-up of pediatric cancers].","authors":"Agathe Camus, Julie Henry, Claire Berger, Amandine Bertrand, Agnès Dumas, Marine Da Silva Sé, Sabine Heinrich, Tanguy Leprince, Gérard Michel, Christelle Riberon, Charlotte Demoor-Goldschmidt","doi":"10.1016/j.bulcan.2024.12.018","DOIUrl":"https://doi.org/10.1016/j.bulcan.2024.12.018","url":null,"abstract":"Introduction: Advances in knowledge about late effects of childhood cancer treatments have led to implement long-term follow-up care. This raises the question of the ethical issues involved in providing information to survivors, and in proposals for long-term follow-up consultations.Method: We conducted a two-part qualitative study: (1) A semi-directive interview survey to explore survivors' experiences of medical proposals for follow-up consultations; (2) The creation of a multidisciplinary ethical reflection group aimed at identifying the ethical issues associated with the systematization of follow-up care.Results: The study identified five key issues related to medical requests and the implementation of follow-up care: (1) The needs and expectations of former patients regarding information; (2) The temporality of after-cancer; (3) The ambivalence of categorizations in light of the diversity of post-cancer experiences; (4) The role of various professionals and the responsibility for follow-up; (5) The plurality of needs and proposed approaches.Discussion: In light of these issues, five areas of concern emerge: (1) Provide information about a risk in life after the disease? (2) When should follow-up be proposed? (3) The category of \"former patients\": relevant or problematic? (4) Who can or should assume the role and responsibility for follow-up? (5) The diversity of follow-up approaches: balancing standardization with reliance on informal networks.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143532233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0